Published in J Immunother Emphasis Tumor Immunol on January 01, 1994
Human albumin administration in critically ill patients: systematic review of randomised controlled trials. BMJ (1998) 22.62
Choice of fluids for resuscitation in children with severe infection and shock: systematic review. BMJ (2010) 1.58
Randomised controlled trial of colloid or crystalloid in hypotensive preterm infants. Arch Dis Child Fetal Neonatal Ed (1997) 1.58
Human albumin and starch administration in critically ill patients: a prospective randomized clinical trial. Wien Klin Wochenschr (2004) 1.51
Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials. Crit Care (2010) 0.98
NK cells in the tumor microenvironment. Crit Rev Oncog (2014) 0.84
Albumin: saint or sinner? Arch Dis Child (1998) 0.83
The appropriate role of colloids in managing fluid imbalance: a critical review of recent meta-analytic findings. Crit Care (2000) 0.78
High-dose IL-2 induces rapid albumin uptake by endothelial cells through Src-dependent caveolae-mediated endocytosis. J Interferon Cytokine Res (2014) 0.77
Nephroprotective Potential of Human Albumin Infusion: A Narrative Review. Gastroenterol Res Pract (2015) 0.75
Cytokine Activation by Antibody Fragments Targeted to Cytokine-Receptor Signaling Complexes. J Biol Chem (2015) 0.75
Hypoalbuminemia at admission predicts the development of acute kidney injury in hospitalized patients: A retrospective cohort study. PLoS One (2017) 0.75
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A (1994) 8.92
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med (1988) 8.90
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med (1982) 8.74
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 8.07
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst (1994) 7.20
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A (1994) 6.93
Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med (1995) 6.77
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 6.36
The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ (2011) 5.95
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother (2001) 5.83
Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol (1998) 5.74
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 5.67
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol (1989) 5.44
Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med (1990) 5.27
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science (1984) 4.90
The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. EMBO J (2000) 4.82
Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med (1996) 4.72
Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases. Cancer (1973) 4.66
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 4.42
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg (1998) 4.35
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am (2000) 4.19
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med (1994) 3.94
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer (2004) 3.75
The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol (1998) 3.68
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A (1999) 3.66
Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol (1989) 3.60
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg (1989) 3.58
A potential role for interleukin-7 in T-cell homeostasis. Blood (2001) 3.56
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol (1996) 3.45
Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med (1995) 3.43
Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol (1990) 3.22
Identification of human cancers deficient in antigen processing. J Exp Med (1993) 3.21
Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol (1996) 3.11
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods (1987) 3.09
Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (1984) 3.08
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med (1997) 3.07
Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med (2001) 3.05
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med (1985) 3.05
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol (2001) 3.05
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol (1998) 3.03
Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol (1987) 3.03
A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med (1999) 3.02
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med (1996) 2.99
The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med (1984) 2.95
NIH conference. Hepatocellular carcinoma. Ann Intern Med (1988) 2.94
High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol (1999) 2.94
The value of laparotomy and splenectomy in the staging of Hodgkin's disease. Cancer (1969) 2.93
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med (1996) 2.92
HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene (2010) 2.91
HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia (2010) 2.83
Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol (1986) 2.82
BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet (2008) 2.79
Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol (1995) 2.78
Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res (1994) 2.74
In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol (1985) 2.73
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am (1997) 2.71
Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med (1996) 2.69
Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med (1983) 2.67
Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet (2000) 2.66
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene (1992) 2.64